Humanwell Healthcare (600079.SH): RFUS-1646 tablets obtained the Drug Clinical Trial Approval Notification.

Humanwell Healthcare (600079.SH) announced that its holding subsidiary Yichang Renfu Pharmaceutical Co., Ltd. (abbreviated as "Yichang Renfu", with the company holding 80% of its equity) recently received the RFUS-1646 tablet "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, allowing it to conduct clinical trials for acute pain (such as postoperative pain). RFUS-1646 is a new molecular entity developed independently by Yichang Renfu, intended for the treatment of acute pain (such as postoperative pain) in clinical practice. Currently, there are no approved drugs with the same target in the domestic market. As of now, Yichang Renfu has accumulated approximately 14 million yuan in research and development investment in this project.